Neisseria gonorrhoeae: symptoms, diagnosis, treatment, and antibiotic resistance

Neisseria gonorrhoeae is the bacterium that causes gonorrhea, one of the most common sexually transmitted infections. It affects the mucous membranes of the genitourinary tract, rectum, pharynx, and conjunctiva, and if untreated, can spread throughout the body and cause serious complications. [1] [2]

The modern significance of this infection is determined not only by its prevalence but also by its ability to remain asymptomatic for long periods. It is precisely asymptomatic and minimally symptomatic forms that support pathogen transmission, delay diagnosis, and increase the risk of pelvic inflammatory disease, infertility, ectopic pregnancy, epididymitis, neonatal infection, and disseminated disease. [3] [4]

A separate reason for the increased attention to Neisseria gonorrhoeae is growing resistance to antimicrobials. The World Health Organization explicitly calls drug-resistant gonorrhea a serious and growing global problem, as the number of reliably effective treatment regimens for the pathogen is rapidly declining. [5] [6]

From a clinical perspective, this means two things. First, it's preferable to confirm the diagnosis microbiologically, not just based on symptoms. Second, even with "common" gonorrhea, physicians today must consider not only the immediate management of the infection but also partner treatment, repeat testing, and potential drug resistance. [7] [8]

Key fact	Practical significance
The pathogen is transmitted sexually	Partners need to be tested and reinfection prevention is needed.
Often asymptomatic	You can't rely solely on complaints
It affects not only the genitourinary organs	It is necessary to take into account the throat, rectum, eyes
May cause serious complications	Early diagnosis and treatment are important
Antibiotic resistance is growing	Up-to-date treatment regimens and monitoring of treatment failures are needed.

The table summarizes current data from the World Health Organization and the US Centers for Disease Control and Prevention.[9] [10] [11]

Epidemiology

According to the World Health Organization, in 2020, there were 82.4 million new cases of gonococcal infection in adults aged 15–49 years worldwide. The African and Western Pacific regions bore the greatest burden of the disease, and the primary age group affected by the infection was the sexually active population aged 15–49 years. [12] [13]

European data also show a marked increase. According to a report from the European Centre for Disease Prevention and Control, 96,969 confirmed cases of gonorrhoea were registered in the European Union and the European Economic Area in 2023, with the notification rate increasing by 31% compared to 2022 and by 321% compared to 2014. [14]

In the United States, the picture has been slightly different in recent years, but the overall burden remains high. The Centers for Disease Control and Prevention reports that gonorrhea cases will decline for the third consecutive year in 2024, by 10% compared to 2023, but the overall national incidence of sexually transmitted infections remains significant. [15] [16]

The risk is unevenly distributed. The World Health Organization and the European Centre for Disease Prevention and Control indicate that prevalence is particularly high among men who have sex with men, sex workers, transgender women, adolescents, and young adults. European statistics show that incidence is increasing particularly rapidly among women aged 20–24. [17] [18] [19]

The most important epidemiological feature of gonorrhea is the large number of unrecognized cases. A significant proportion of infections are asymptomatic, especially in women and in cases involving the pharynx and rectum. This makes screening of at-risk groups and repeat testing after treatment an important part of infection control at the population level. [20] [21] [22]

Indicator	Current data
Worldwide, new cases in 2020	82.4 million
The European Union and the European Economic Area, 2023	96,969 confirmed cases
Growth in Europe compared to 2014	321%
Growth in Europe compared to 2022	31%
US, 2024 to 2023 dynamics	10% reduction

The table is compiled using data from the World Health Organization, the European Centre for Disease Prevention and Control, and the US Centers for Disease Control and Prevention. [23] [24] [25]

Structure of the pathogen

Neisseria gonorrhoeae is a Gram-negative diplococcus. Microscopically, the bacteria are typically seen in pairs, with adjacent cell sides appearing flattened. This classic morphological appearance still has diagnostic value, particularly when examining stained urethral smears in symptomatic men. [26] [27]

The surface of the gonococcus contains pili, which play a role in attachment to host cells. In addition to pili, Opa proteins and other components of the outer membrane are involved in adhesion. These surface structures help the pathogen attach to the mucosa, penetrate the epithelium, and remain at the site of infection. [28] [29]

An important feature of gonococci is the variability of their surface structures. Phase and antigenic variability have been described for the pili and Opa proteins, allowing the bacteria to better evade the immune response and maintain the ability to cause repeated infections in the same individual. This is one of the reasons why naturally acquired gonorrhea does not provide reliable, long-term protection. [30] [31]

The pathogenicity of Neisseria gonorrhoeae is also associated with the lipo-oligosaccharide of the outer membrane. It stimulates the inflammatory response, promotes tissue damage, and enhances the clinical manifestations of infection. It is this combination of adhesion factors, variability, and inflammatory potential that makes the gonococcus a particularly successful human pathogen. [32] [33]

Structural element	Role
Diplococcal form	Classic microscopic sign
We drank	Primary attachment to the epithelium
Opa Squirrels	Strengthening adhesion and invasion
Lipooligosaccharide	Inflammation and tissue damage
Phase and antigen variability	Evasion of the immune response

The table is based on data from the US National Library of Medicine and the US National Institutes of Health. [34] [35]

Life cycle

Neisseria gonorrhoeae does not have a complex life cycle with intermediate hosts or external stages, as do parasites. It is a strictly human pathogen, transmitted primarily through vaginal, anal, and oral sex, as well as from mother to child during childbirth. In other words, its life cycle is human-mucosal-human. [36] [37]

Once transmitted, the bacteria attach to the mucous membrane and begin local colonization. The most common primary sites are the urethra, endocervix, rectum, and pharynx. The clinical course depends on the site of entry: for example, urethral infection in men is often severe, while pharyngeal and rectal forms are often asymptomatic. [38] [39]

The pathogen then penetrates the epithelial layer, multiplies, and maintains inflammation. In uncomplicated cases, the process remains localized. In complicated cases, the infection ascends the genitourinary tract or enters the bloodstream, leading to pelvic inflammatory disease, epididymitis, arthritis, tenosynovitis, skin lesions, and, in rare cases, endocarditis or meningitis. [40] [41]

A clinically important stage of the life cycle is reinfection. The US Centers for Disease Control and Prevention emphasize that a significant proportion of recurrent positive cases after treatment are not due to true treatment failure, but to reinfection from an untreated partner or a new infected contact. Therefore, for gonorrhea, the life cycle of the pathogen is closely linked to the sexual network and partner treatment. [42] [43]

Stage	What's happening
Broadcast	Sexual contact or vertical transmission during childbirth
Colonization	Attachment to the mucous membrane
Invasion	Penetration into the epithelium and local proliferation
Local inflammation	Urethritis, cervicitis, proctitis, pharyngitis, conjunctivitis
Ascending or hematogenous spread	Complicated and disseminated forms
Reinfection	Reinfection after treatment

The table reflects the current clinical understanding of the life cycle of gonococcal infection.[44] [45] [46]

Pathogenesis

Pathogenesis begins with the attachment of the bacterium to non-ciliary columnar epithelial cells. Pili and Opa proteins ensure contact with the mucosa, after which the gonococcus penetrates the superficial cells and begins local reproduction. The ability to attach to specific areas of the mucosa is particularly important for the pathogen, where it subsequently causes urethritis, cervicitis, or proctitis. [47] [48]

Following adhesion, the host's inflammatory response is triggered. Lipooligosaccharide and other bacterial surface components stimulate the release of inflammatory mediators, neutrophil influx, and tissue damage. This is why many patients experience purulent discharge, painful urination, hyperemia, and mucosal tenderness. [49]

At the same time, the pathogen is able to partially evade immune defense. Phase and antigen variability of pili and Opa proteins, as well as the ability to resist complement in some strains, complicate bacterial elimination and create conditions for persistence or dissemination. Strains resistant to serum and complement are particularly at risk of generalization. [50] [51]

If the local barrier fails to contain the infection, the process either ascends the urogenital tract or spreads hematogenously. This leads to pelvic inflammatory disease in women, epididymitis in men, and disseminated gonococcal infection with cutaneous-articular syndrome, septic arthritis, and, in rare cases, meningitis or endocarditis. [52] [53]

Pathogenetic stage	Clinical outcome
Attachment to the epithelium	Onset of local infection
Invasion of the mucosa	Formation of a focus of inflammation
Pronounced neutrophilic reaction	Purulent discharge and dysuria
Evasion of the immune response	Persistence and relapses
Ascending or hematogenous spread	Complications and dissemination

The table is based on materials from the US National Library of Medicine and official clinical guidelines from the US Centers for Disease Control and Prevention. [54] [55]

Symptoms

Gonorrhea symptoms vary greatly depending on gender and the anatomical location of the infection. The World Health Organization (WHO) states that symptoms typically appear 1-14 days after sexual contact with an infected person, but a significant proportion of cases remain asymptomatic. Therefore, the absence of symptoms does not rule out infection or reduce its epidemiological significance. [56]

In men, the most common symptoms are pain or burning during urination and white, yellow, or greenish discharge from the urethra. Pain or swelling in the testicular area is possible, especially if epididymitis develops. The urethral form in men is more often symptomatic, so male patients often seek treatment earlier. [57] [58]

In women, the presentation is often less specific. Vaginal discharge, dysuria, intermenstrual bleeding, contact bleeding, and lower abdominal pain are possible, but many women do not notice any symptoms or perceive them as "normal inflammation." This creates conditions for late diagnosis and the ascending spread of infection. [59] [60]

Rectal infections in both men and women can present with itching, discharge, bleeding, soreness, and pain during bowel movements, but are often subtle. Pharyngeal infections are even more insidious: they often lack obvious symptoms and are sometimes limited to redness and sore throat. Conjunctival infections are accompanied by purulent inflammation of the eye and require immediate medical attention. [61] [62]

In disseminated infection, symptoms extend beyond localized urethritis or cervicitis. Characteristic features include fever, skin rashes, asymmetric polyarthralgia, tenosynovitis, oligoarthritis, and, in rare cases, signs of cardiac or meningeal damage. This clinical picture requires immediate, comprehensive evaluation. [63] [64]

Localization	The most typical symptoms
Urethra	Burning, purulent discharge
Cervix	Discharge, dysuria, contact bleeding
Rectum	Pain, itching, discharge, bleeding
Pharynx	Often asymptomatic, sometimes with a sore throat
Conjunctiva	Purulent inflammation of the eye
Dissemination	Fever, arthritis, tenosynovitis, skin lesions

The table is based on data from the World Health Organization and the US Centers for Disease Control and Prevention.[65] [66] [67]

Stages

Gonorrhea does not have a single, universal staging system recognized by all international guidelines as formally as the staging of malignant tumors. Therefore, it is more appropriate to speak of stages in a clinical rather than a strictly nosological sense. In practice, physicians typically think in sequential order: incubation, localized uncomplicated infection, complicated ascending course, or dissemination. [68] [69]

The first stage is the incubation period and early colonization of the mucous membrane. During this time, there may be no symptoms, but the bacteria are already being transmitted to partners. This is followed by the local stage, when urethritis, cervicitis, proctitis, pharyngitis, or conjunctivitis develop. It is at this stage that the disease can most often be cured quickly and without consequences. [70]

If diagnosis is delayed, a complicated stage begins. For women, this most often involves an ascending infection involving the uterus, fallopian tubes, and pelvic organs; for men, epididymitis and other inflammatory complications; and for both sexes, the possibility of disseminated gonococcal infection. It's important to be clear that there are no strict time limits between these stages: the transition is determined not by the calendar, but by the behavior of the pathogen and the body's response. [71] [72]

Conditional stage	What's happening
Incubation	There are no or almost no symptoms, transmission is already possible
Local infection	Urethritis, cervicitis, proctitis, pharyngitis
Ascending complicated course	Inflammatory lesions of the upper urogenital tract
Dissemination	Skin, joints, tendons, rarely heart and central nervous system

This table describes the clinical, rather than formally internationally standardized, staging of gonorrhea.[73][74]

Forms

Based on localization, the disease is classified into urogenital, rectal, pharyngeal, conjunctival, neonatal, and disseminated forms. This classification is useful because it defines the symptoms, the material for analysis, and the requirements for monitoring the cure. It is especially important to remember that a single patient may have multiple localizations simultaneously. [75] [76]

Based on the course of the disease, it is convenient to distinguish between uncomplicated and complicated gonorrhea. Uncomplicated forms are limited to the primary lesion, while complicated forms are accompanied by ascending infection, pelvic inflammatory disease, epididymitis, dissemination, septic arthritis, meningitis, or endocarditis. It is this distinction that has a greater influence on the choice of treatment than the question of "acute or chronic." [77] [78]

From a practical standpoint, another form of the disease—asymptomatic—is also important. It is no less significant than symptomatic cases, as these cases often remain undetected and become a source of further transmission. Therefore, screening of women under 25, pregnant women in high-risk groups, and men who have sex with men remains the cornerstone of prevention. [79] [80] [81]

Classification	Options
By localization	Urogenital, rectal, pharyngeal, conjunctival
By severity	Uncomplicated, complicated
Around the clinic	Symptomatic, asymptomatic
By age context	Adult, neonatal
By prevalence	Local, disseminated

The table is based on the clinical criteria of the World Health Organization and the US Centers for Disease Control and Prevention.[82] [83]

Complications and consequences

In women, the most common complications are pelvic inflammatory disease, tubal infertility, and ectopic pregnancy. The World Health Organization emphasizes that untreated gonorrhea can lead to these reproductive consequences, often with subtle initial symptoms. [84]

In men, complications more often include epididymitis, scrotal pain and swelling, urethral strictures, and subsequent decreased fertility. Although male urethral forms often present more prominently, late diagnosis and undertreatment can also lead to long-term consequences. [85] [86]

Rectal, pharyngeal, and disseminated complications are important for both sexes. Disseminated gonococcal infection can present with fever, pustular or petechial skin lesions, tenosynovitis, septic arthritis, and, less commonly, endocarditis and meningitis. This is no longer simply a localized mucosal infection but a potentially life-threatening condition. [87] [88]

Obstetric and neonatal consequences should be highlighted separately. Gonorrhea in a pregnant woman increases the risk of complications during pregnancy, and during childbirth, the pathogen can be transmitted to the child, resulting in gonococcal conjunctivitis. Left untreated, this eye infection can lead to corneal ulcers and blindness. [89] [90] [91]

In addition to organ complications, gonorrhea has significant societal consequences. Infection increases the risk of transmission and acquisition of the human immunodeficiency virus, maintains the circulation of other sexually transmitted infections, and places a heavy burden on the healthcare system due to recurrent episodes and drug resistance. [92] [93]

Complication	Who does it occur in more often?	What is dangerous?
Inflammatory diseases of the pelvic organs	Women	Infertility, chronic pain, ectopic pregnancy
Epididymitis	Men	Pain, swelling, decreased fertility
Disseminated infection	Both sexes	Arthritis, skin lesions, sepsis-like course
Gonococcal conjunctivitis of the newborn	Newborns	Corneal damage, blindness
Increased risk of transmission of human immunodeficiency virus	Both sexes	Additional public and clinical risk

The table summarizes the complications confirmed by international recommendations and official information resources. [94] [95] [96]

Diagnostics

The current standard of diagnosis is microbiological confirmation of infection. The US Centers for Disease Control and Prevention emphasizes that specific testing for Neisseria gonorrhoeae should be performed in all individuals suspected of having gonorrhea or at increased risk, as this reduces the incidence of complications, reinfections, and transmission. [97]

Today, nucleic acid amplification tests have the highest sensitivity. According to the World Health Organization, molecular tests are considered the "gold standard" of diagnostics, and the US Centers for Disease Control and Prevention (CDC) notes that their sensitivity in urogenital and extragenital locations is generally higher than that of culture, although specific indicators depend on the platform and anatomical site. [98] [99]

The sample for testing is selected based on the suspected location. For men, the optimal urogenital sample is the first portion of urine, for women, a vaginal swab, and for those with sexually transmitted diseases, swabs from the rectum and pharynx are required. This is crucial, as an isolated pharyngeal or rectal infection may be missed if only urine is collected. [100] [101]

Stained smear microscopy remains valuable, but not universally. In symptomatic men with urethral discharge, detection of intracellular Gram-negative diplococci in smears is highly sensitive and specific and can be considered diagnostic. For endocervical, rectal, and pharyngeal specimens, this approach is insufficiently sensitive and is not routinely recommended. [102]

Culture remains indispensable in certain situations. It is necessary when treatment failure is suspected, when drug resistance is possible, and when antibiotic susceptibility testing is necessary, as molecular tests do not provide a complete phenotypic picture of resistance. The US Centers for Disease Control and Prevention specifically recommends that both culture and molecular testing be performed simultaneously if treatment failure is suspected. [103] [104]

Instrumental diagnostics for uncomplicated gonorrhea are not essential. They are necessary in the case of complications. For example, if pelvic inflammatory disease is suspected, the US Centers for Disease Control and Prevention recommends transvaginal ultrasound, magnetic resonance imaging, and laparoscopy. In the case of disseminated infection, the physician additionally evaluates for signs of arthritis, meningitis, and endocarditis and examines the corresponding organs and fluids. [105] [106]

Rapid point-of-care tests are also emerging. In 2025, the US Food and Drug Administration approved new, fully automated molecular solutions for rapid detection of gonococcus, including a male urine test with results in approximately 30 minutes. This does not replace laboratory diagnostics, but it points to a direction of development—towards faster verification and earlier treatment. [107]

Method	What does it give?	Restrictions
Nucleic acid amplification test	The most sensitive routine diagnostic test	Does not induce phenotypic sensitivity to antibiotics
Culture	Allows you to test sensitivity	Demanding in terms of collection and transportation
Microscopy of urethral smear in symptomatic men	Quick indicative confirmation	Doesn't work well on the cervix, throat, and rectum.
Rapid molecular testing at the point of care	Speeds up decision making	Availability is limited at this time.
Instrumental diagnostics	Needed in case of complications	Does not replace microbiological confirmation

The table is based on recommendations from the World Health Organization, the US Centers for Disease Control and Prevention, and the US Food and Drug Administration.[108] [109] [110]

Differential diagnosis

In real-life practice, gonococcal urethritis and cervicitis most often have to be differentiated from chlamydial infection. Both infections can coexist, so denial of one does not exclude the other, and when a complete set of results is unavailable, the treatment regimen often must consider both possible causes. This is why current guidelines specifically recommend the addition of antichlamydial therapy if chlamydial infection cannot be ruled out. [111] [112]

In men, dysuria and discharge also require the exclusion of non-gonococcal urethritis of other origins, including those caused by Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas, and some viral infections. In women, the differential diagnosis is even broader and includes bacterial vaginosis, vulvovaginal candidiasis, pelvic inflammatory disease without confirmed gonococcal etiology, and cervicitis of mixed origin. [113] [114]

Pharyngeal gonorrhea must be distinguished from common viral or bacterial pharyngitis, and rectal gonorrhea must be distinguished from other causes of proctitis and proctocolitis, including chlamydial infection, syphilis, herpesvirus infection, and intestinal causes. Due to the poor specificity of symptoms, extragenital forms are often underestimated unless the physician collects a sexual history and takes swabs from the relevant areas. [115] [116]

When women experience lower abdominal pain or men experience acute scrotal syndrome, the task changes. Here, the physician must differentiate not just localized gonorrhea, but its complications from appendicitis, testicular torsion, non-gonococcal epididymitis, acute cystitis, urolithiasis, and other causes of acute inflammatory syndrome. Therefore, clinical differential diagnosis should always be combined with laboratory confirmation, not replace it. [117] [118]

What is gonorrhea most often confused with?	Why does confusion arise?
Chlamydial infection	Similar symptoms of urethritis and cervicitis
Non-gonococcal urethritis	Dysuria and discharge without typical microscopy
Bacterial vaginosis and candidiasis	Discharge and discomfort in women
Common pharyngitis	Pharyngeal gonorrhea is often asymptomatic
Proctitis of another nature	Rectal forms are nonspecific

The table reflects the practical range of differential diagnostics according to modern clinical guidelines. [119] [120] [121]

Treatment

The main principle of treatment is that therapy should be initiated promptly and according to an up-to-date regimen. According to current clinical guidelines from the US Centers for Disease Control and Prevention, the standard treatment for uncomplicated gonococcal infection of the cervix, urethra, and rectum in adolescents and adults remains ceftriaxone 500 mg intramuscularly once for individuals weighing less than 150 kg and 1 g intramuscularly once for individuals weighing 150 kg or more. If chlamydial infection cannot be ruled out, doxycycline 100 mg orally twice daily for 7 days is added. [122] [123]

For pharyngeal gonorrhea, the requirements are more stringent. The US Centers for Disease Control and Prevention emphasize that ceftriaxone remains a reliable baseline regimen, while reliable alternatives for the pharyngeal form are significantly fewer. Any patient with a gonococcal pharyngeal infection should undergo a test of cure 7-14 days after treatment. [124] [125]

If ceftriaxone is unavailable or impossible to administer, an alternative regimen with cefixime 800 mg orally as a single dose is acceptable, but it is considered only as a backup. This regimen is inferior to ceftriaxone in terms of the stability of bactericidal concentrations and is less effective against pharyngeal gonorrhea. If chlamydial infection cannot be ruled out, antichlamydial treatment is also mandatory. [126]

In cases of severe allergy to cephalosporins, an alternative combination of gentamicin 240 mg intramuscularly as a single dose plus azithromycin 2 g orally as a single dose is possible. However, this regimen cannot be considered an equivalent universal replacement: it is more often accompanied by adverse gastrointestinal effects and has been less well studied for some non-genital localizations. [127]

The treatment strategy for complicated forms and dissemination differs. For gonococcal arthritis and arthritis-dermatitis syndrome, the US Centers for Disease Control and Prevention recommend ceftriaxone 1 g intramuscularly or intravenously every 24 hours, followed by a transition to an oral drug based on susceptibility after clinical improvement, for a total duration of at least 7 days. For meningitis and endocarditis, ceftriaxone 1-2 g intravenously every 12-24 hours is used, with treatment continuing for 10-14 days for meningitis and for more than 4 weeks for endocarditis. [128]

Treatment monitoring is essential. For uncomplicated urogenital and rectal gonorrhea, monitoring of cure after adequate therapy is usually not required. For the pharyngeal form, it is mandatory. If a molecular test is positive after treatment, confirmatory culture and susceptibility testing should be performed, especially if therapeutic failure is suspected. Furthermore, all treated patients are recommended to be retested after 3 months, as reinfection is common. [129] [130]

A new and truly important topic in recent months is the emergence of new-generation oral medications. In December 2025, the U.S. Food and Drug Administration approved zoliflodacin for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents 12 years and older weighing at least 35 kg. The regimen is 3 g orally as a single dose as a suspension to be taken after dilution with water. This is the first approved oral medication of a new class for this infection, but the indication is limited specifically to uncomplicated urogenital gonorrhea. [131] [132]

Also in December 2025, the US Food and Drug Administration expanded the indication for gepotidacin to include uncomplicated urogenital gonorrhea in adults and adolescents 12 years and older weighing at least 45 kg with limited or no alternative treatment options. The regimen is 3,000 mg orally, then another 3,000 mg 12 hours later. However, this drug has clinically significant limitations, including the risk of prolonging the QTc interval, a high incidence of gastrointestinal adverse events, and a narrower clinical niche. Therefore, it cannot automatically replace the standard ceftriaxone regimen. [133] [134] [135] [136]

Finally, gonorrhea treatment never ends with a shot or pills for one patient. It is important to abstain from sexual intercourse for 7 days after treatment and until partners have completed treatment, have partners tested for the past 60 days, and, if necessary, use expedited partner treatment where legally permitted. If it is not possible to quickly bring a partner for an in-person appointment, the US Centers for Disease Control and Prevention (CDC) allows for expedited partner treatment with cefixime 800 mg and, if chlamydial status is unknown, with the addition of doxycycline. [137] [138] [139]

Clinical situation	Current tactics
Uncomplicated urogenital, cervical, urethral or rectal form	Ceftriaxone 500 mg intramuscularly once, or 1 g for body weight of 150 kg or more
Chlamydial infection cannot be ruled out	Add doxycycline 100 mg 2 times a day for 7 days
There is no possibility to administer ceftriaxone	Cefixime 800 mg orally once as an alternative
Severe allergy to cephalosporins	Gentamicin 240 mg intramuscularly plus azithromycin 2 g orally
Pharyngeal form	Ceftriaxone, then mandatory control of cure after 7-14 days
Disseminated infection	Parenteral treatment with ceftriaxone, often with hospitalization
New drugs	Zoliflodacin and gepotidacin only for uncomplicated urogenital forms and taking into account the limitations of indications

The table is compiled based on current recommendations from the US Centers for Disease Control and Prevention and the US Food and Drug Administration guidelines approved by the end of 2025. [140] [141] [142] [143] [144]

Prevention

Primary prevention of gonorrhea remains primarily behavioral and organizational. The World Health Organization emphasizes that most cases can be prevented with correct and consistent use of condoms during every sexual encounter. This remains the most accessible and proven method for reducing transmission of infection. [145]

Screening is equally important. The U.S. Centers for Disease Control and Prevention recommends annual gonorrhea testing for all sexually active women under 25, women 25 and older at high risk, and men who have sex with men at least annually and more frequently, every 3 to 6 months, if at high risk. Pregnant women at risk are tested early in pregnancy and again in the third trimester. [146] [147] [148]

Secondary prevention includes mandatory retesting after treatment and treatment of partners. Since reinfection is common, retesting after three months is not a formality, but a real way to break the chain of transmission and avoid mistaking reinfection for a "failed antibiotic." [149] [150]

A separate preventive strategy is in place for newborns. The U.S. Centers for Disease Control and Prevention recommends that all newborns receive prophylactic erythromycin ophthalmia ointment as soon as possible after birth, regardless of the mode of delivery, to prevent gonococcal ophthalmia neonatorum. [151]

Finally, new preventive approaches include post-exposure doxycycline in select groups. In 2024, the US Centers for Disease Control and Prevention issued clinical guidelines for the use of doxycycline after sexual exposure for certain men who have sex with men and transgender women with recent sexually transmitted bacterial infections. This strategy does not replace screening and condoms and is not universally applicable, but it reflects a shift toward more active prevention in very high-risk groups. [152]

There is currently no specific vaccine against gonorrhea. The World Health Organization reports that specific gonococcal vaccines are not yet available, but studies show promising signs of cross-protection with the meningococcal type B vaccine 4CMenB. This is not yet standard gonorrhea prophylaxis for widespread use, but it appears to be a very promising direction. [153] [154]

Preventive measure	Role
Condoms	Reducing the risk of transmission through any type of sexual contact
Screening of risk groups	Identification of asymptomatic cases
Retest after 3 months	Search for reinfection
Treatment of partners	Breaking the chain of transmission
Eye prevention in newborns	Prevention of ophthalmia neonatorum
Vaccine development and targeted antibiotic prophylaxis	New directions of prevention

The table is based on official data from the World Health Organization and the US Centers for Disease Control and Prevention.[155] [156] [157] [158]

Forecast

With timely diagnosis and adequate treatment, the prognosis for most patients is good. Uncomplicated localized forms usually resolve without long-term consequences, especially if treatment is started before the infection spreads upward and if sexual partners are treated simultaneously. [159] [160]

The prognosis worsens in three circumstances: asymptomatic progression with late detection, repeated infections, and complicated forms. These factors increase the likelihood of pelvic inflammatory disease, epididymitis, infertility, chronic pelvic pain, and systemic complications. Therefore, a favorable prognosis depends not only on the antibiotic itself, but also on screening, partner treatment, and repeat testing. [161] [162]

Antibiotic resistance also affects the population prognosis. The World Health Organization and surveillance systems in Europe are noting rising resistance to key drugs, including increasing problems with ceftriaxone and azithromycin in some regions. This does not mean that gonorrhea has already become universally untreatable, but it does mean that without surveillance and updated regimens, the long-term prognosis for infection control will worsen. [163] [164] [165]

FAQ

Can you become infected with gonorrhea through kissing or casual contact?
The primary modes of transmission are vaginal, anal, and oral sex, as well as transmission to the child during childbirth. There are no compelling routine grounds for casual transmission, so sexual contact remains the key route in clinical practice. [166] [167]

If there are no symptoms, is the infection still dangerous?
Yes. Asymptomatic forms are very important epidemiologically and clinically, because a person continues to transmit the bacteria and can develop complications without even realizing it. This is especially true for women, as well as for pharyngeal and rectal forms. [168] [169]

Is a single urine test sufficient?
Not always. For men with urogenital lesions, the first portion of urine is sufficient, but for women, a vaginal swab is preferable, and in cases of oral and anal contact, pharyngeal and rectal swabs are essential. Otherwise, extragenital lesions may be missed. [170]

Should a partner be treated if they have no complaints?
Yes. Partners exposed to the virus for the past 60 days are subject to assessment, testing, and presumptive treatment, that is, treatment based on epidemiological indications. Otherwise, the risk of reinfection remains very high. [171] [172]

Can gonorrhea be cured with pills alone?
Ceftriaxone remains the standard of care in routine current practice. However, new oral medications for uncomplicated urogenital gonorrhea became available in the United States in late 2025, but their indications are limited and they have not automatically replaced the standard regimen for all sites and clinical situations. [173] [174] [175]

Is post-treatment monitoring necessary?
For uncomplicated urogenital and rectal gonorrhea, monitoring of cure is usually not necessary if an adequate regimen is used. For pharyngeal gonorrhea, monitoring is mandatory after 7-14 days. Furthermore, all patients are recommended to be retested after 3 months due to the high rate of reinfection. [176] [177]

Key points from experts

Kimberly A. Workowski, MD, chair of the Centers for Disease Control and Prevention's Sexually Transmitted Infections Guidelines Task Force and a member of the Centers for Disease Control and Prevention and Emory University, explains her position on current U.S. guidelines: Gonorrhea should not be treated with the same old habits. The regimen should be consistent with current data on resistance, and patient management should include not only treatment but also co-infection screening, retesting, and partner management. [178] [179] [180]

Laura H. Bachmann, MD, MPH, chief medical officer, Division of Sexually Transmitted Infection Prevention, U.S. Centers for Disease Control and Prevention. Her contribution to current clinical guidelines emphasizes that the fight against gonorrhea has long since moved beyond a single antibiotic injection. Today, it involves a combination of therapy, resistance surveillance, screening, and behavioral prevention in high-risk groups. [181] [182]

Robert D. Kirkcaldy, MD, is an expert at the U.S. Centers for Disease Control and Prevention (CDC) in gonococcal surveillance and drug resistance. His work on the Gonococcal Isolate Surveillance Project and drug-resistant gonorrhea demonstrates a key point: laboratory surveillance of pathogen susceptibility is not an academic luxury but the foundation for maintaining effective treatment. It is precisely through programs like these that recommendations are changed and the threat of declining susceptibility to ceftriaxone can be detected before it becomes a clinical disaster. [183] [184]

Magnus Unemo, MD, PhD, is a leading international expert on gonorrhea, involved with World Health Organization programs and European resistance surveillance. His line of work is particularly important for the future: gonorrhea remains curable, but the window of opportunity is not infinite. Therefore, new drugs, the development of rapid tests, improved surveillance, and vaccine development are not optional extras, but a strategic imperative. [185] [186] [187]